Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01327469
Other study ID # 2010/517
Secondary ID
Status Completed
Phase Phase 4
First received March 30, 2011
Last updated March 31, 2011
Start date December 2010
Est. completion date March 2011

Study information

Verified date March 2011
Source University Ghent
Contact n/a
Is FDA regulated No
Health authority Belgium: Ethics Committee
Study type Interventional

Clinical Trial Summary

The major soil-transmitted helminths (STHs), Ascaris lumbricoides (roundworm), Trichuris trichiura (whipworm) and Necator americanus/Ancylostoma duodenal (hookworms) are amongst the most prevalent parasites worldwide. An estimated 4.5 billion individuals are at risk for STH and more than one billion individuals are thought to be infected, of which 450 million have significant morbidity attributable from their infection, school-aged children in particular. In this population infections cause stunting of the linear growth, anemia, reduce the cognitive function and contribute to the existing malnutrition. In Jimma (Ethiopia), STH are highly prevalent, affecting more than 60% of the children (data not published).

Current efforts to control STH infections involve periodic mass drug anthelmintic treatment of infected children in endemic areas and are likely to intensify as more attention is addressed to the importance of these neglected diseases. Monitoring drug efficacy in these control programs has become indispensable in order to detect the emergence of resistance and/or identify confounding factors affecting the drug efficacy. Recently a study has evaluated a single dose albendazole (ALB) in school age children across 7 countries, including Ethiopia, revealing that this regime is highly efficacious for the treatment of A. lumbricoides (99.5%) and hookworms (94.8%), but not for T. trichiura (50.8%). For this parasite a repeated dose regime of ALB on consecutive days is likely to be more appropriate. Alternative drugs are mebendazole (single dose 500mg) and pyrantel+oxantel (single dose 10mg/kg), of which the latter holds promise as it can also be administrated to children between 6 months and 2 years. The main objective of the present study, therefore, is to assess the efficacy of 5 different treatment regimes against T. trichiura in schoolchildren in Jimma, Ethiopia, including albendazole (1 x 400mg, 2 x 400mg), mebendazole (1 x 500mg, 2x 500mg) and pyrantel-oxantel (10mg/kg)+mebendazole (500mg).


Recruitment information / eligibility

Status Completed
Enrollment 2250
Est. completion date March 2011
Est. primary completion date February 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 4 Years to 18 Years
Eligibility Inclusion Criteria:

- all school age children who are eligible to participate in the study

Exclusion Criteria:

- Not willing to participate (no informed consent)

- Unable to give samples for follow up

- Severe intercurrent medical condition

- Diarrhea at first sampling

- Study subjects who had treatment for STH in the last 3 months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Albendazole, 2 x 400mg
Albendazole 2 x 400mg
Albendazole 400mg
Albendazole 400mg
Mebendazole 500mg
Mebendazole 500mg
Mebendazole 2 x 500mg
Mebendazole 2 x 500mg
Pyrantel-oxantel + mebendazole
Pyrantel-oxantel + mebendazole

Locations

Country Name City State
Ethiopia Jimma University Jimma

Sponsors (2)

Lead Sponsor Collaborator
University Ghent VLIR-UOS Institutional University Cooperation

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy against T. trichiura of various treatment regimes The evaluation of the efficacy against T. trichiura of various treatment regimes. To this end, subjects infected with T. trichura (based on McMaster), will be randomly assigned to one of the five proposed treatment regimes. Two weeks after the treatment, faecal egg counts will be performed and the reduction in faecal egg counts will be evaluated After two weeks treatment No